Clinical trials: Antiretroviral Therapy
HIV Infections, Acquired Immunodeficiency Syndrome
Medications for Chronic HIV: Education and Collaboration
This study will examine whether a computerized, self-administered assessment of patient medication adherence and health behaviors, plus support for adherence, improves the ability of clinicians to identify adherence problems and…
- Conditions
- HIV Infections, Acquired Immunodeficiency Syndrome, Medication Adherence
- Trial name
- MedCHEC (NCT01038076)
- Testing
- MedCHEC Tablet Computer & Adherence Care
- Where
- 3 sites in United States
- Volunteers
- 371 people
- Sponsor
- Boston University
HIV-1 Infection
The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients
This study evaluate the safety of UB-421 in combination with standard antiretroviral therapy (ART) and the efficacy of HIV reservoir reduction as compared with ART alone in ART stabilized HIV-1 patients
- Trial name
- NCT03743376
- Testing
- UB-421(25 mg/kg) Q2W, UB-421(25 mg/kg) Q4W
- Where
- 3 sites in Taiwan
- Volunteers
- 31 people
- Sponsor
- United BioPharma
Stimulant Use Disorder, People Living With HIV
reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)
The purpose of this study is to find out if reSET, an FDA authorized mobile therapeutic, is effective in treating stimulant use disorder and helping keep HIV viral load suppression stable among men who have sex with men who are…
- Trial name
- COSTA (NCT05958017)
- Testing
- reSET, Standard of care
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- University of Miami
Coronary Heart Disease, Heart Failure
Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 7.5 Years Follow-up
Since the introduction of antiretroviral therapy life expectancy of HIV-infected persons is rising. Different cohorts are observing an increased risk for cardiovascular diseases in this aging HIV-infected population.
- Conditions
- Coronary Heart Disease, Heart Failure, HIV, AIDS
- Trial name
- NCT01667068
- Testing
- Comprehensive non invasive cardiovascular examination
- Where
- 6 sites in Germany
- Volunteers
- 1,481 people
- Sponsor
- University Hospital, Essen
HIV Infections
RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART)
The objectives of this clinical trial are to: Assess the safety of using extracorporeal photoimmune therapy with the photosensitizing agent Uvadex in the treatment of HIV-1 infection; Evaluate the effects of this therapy on HIV-1…
- Trial name
- HIV-HAART (NCT00157027)
- Testing
- Extracorporeal photochemotherapy with UVADEX
- Sponsor
- Atlantic Health System
HIV Infections
Study of Pharmacokinetics in HIV-infected Women
Women represent an increasing proportion of HIV cases globally and in Canada, yet are underrepresented in clinic trials. It is therefore critical to conduct this study on antiretroviral (ARV) pharmacokinetics (PK) in women to…
- Trial name
- NCT00433979
- Testing
- antiretroviral treatment
- Where
- 15 sites in Canada
- Volunteers
- 88 people
- Sponsor
- Women's College Hospital
HIV Infections, HIV Prevention
Community-based Outreach and Navigation for Nurse-led Engagement in HIV Care and Treatment
Many people who are experiencing homelessness are at high risk for HIV, but they often have trouble getting HIV prevention or treatment.
- Conditions
- HIV Infections, HIV Prevention, Homeless Persons, Homelessness
- Trial name
- CONNECT (NCT07870603)
- Testing
- CONNECT (status-neutral, nurse-led on-site HIV service delivery), Standard of Care (referral-based outreach)
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Donaldson Conserve
HIV-1 Infection
Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)
This study aims to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-retroviral therapy (ART) activity of monotherapy with MK-8504 (a tenofovir pro-drug), in ART-naïve Human Immunodeficiency Virus (HIV)-1…
- Trial name
- NCT03188523
- Testing
- MK-8504
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV, Hyperlipidemia
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
The success of combination antiretroviral therapy heralded a revolution in the treatment of HIV in the mid-1990s. However, severe treatment-associated side effects have been observed including diabetes and increased cholesterol…
- Conditions
- HIV, Hyperlipidemia, Hypertriglyceridemia, HIV Infections
- Trial name
- NCT00887653
- Testing
- raltegravir
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- The Miriam Hospital
HIV - Human Immunodeficiency Virus
Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy
The purpose of this trial is to evaluate the immunomodulatory effects of glatiramer acetate (GA) in improving the recovery of CD4 T cells and the CD4/CD8 ratio in people living with HIV (PLWHIV) who have poor immune recovery and…
- Trial name
- GEODE (NCT07851337)
- Testing
- - Study treatment arm group (Arm A): GLATIRAMER VIATRIS 40mg/ml
- Volunteers
- 36 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV, Cardiovascular Disease
Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.
This is a research study into the effects of three drugs used to treat HIV infection. Some drugs used to treat HIV have been associated with changes in blood fats such as cholesterol that could be harmful over the long-term…
- Trial name
- ROaR+ (NCT01258439)
- Testing
- raltegravir plus truvada, Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)
- Where
- 2 sites in Australia
- Volunteers
- 25 people
- Sponsor
- St Vincent's Hospital, Sydney
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants
The primary objectives of this study are to evaluate the safety, tolerability and steady-state PK and confirm the dose of EVG/r in HIV-1 infected, antiretroviral treatment-experienced children 4 weeks to <18 years of age.
- Trial name
- NCT01923311
- Testing
- EVG, Background regimen
- Where
- 11 sites in United States, Italy and 4 more
- Volunteers
- 31 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation
This is a mixed prospective-retrospective, multi-center observational study to assess the virologic effectiveness of generic product of Lopinavir/Ritonavir (LPV/r) after switching from Kaletra in the routine clinical settings of…
- Trial name
- COPI (NCT04138199)
- Where
- 10 sites in Russia
- Volunteers
- 239 people
- Sponsor
- AbbVie
HIV
Integrating U=U Into HIV Counseling in South Africa (INTUIT-2.0)
Undetectable = Untransmittable (U=U) is the scientific consensus that people with human immunodeficiency virus (HIV) who achieve viral suppression through antiretroviral treatment (ART) cannot transmit the virus sexually.
- Trial name
- NCT07199634
- Testing
- "Undetectable & You" HIV treatment literacy app
- Volunteers
- 880 people
- Sponsor
- Boston University
HIV Infections
A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs
The purpose of this study is to see if it is safe to give tucaresol to HIV-infected patients who are taking combination anti-HIV therapy (HAART).
- Trial name
- NCT00006209
- Testing
- Tucaresol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Aaron Diamond AIDS Research Center
HIV Infection
A Study of Health-Related Quality of Life in HIV-Infected Patients Undergoing Structured Treatment Interruptions of Highly Active Antiretroviral Therapy
This study will examine and compare the health-related quality of life and degree of symptom discomfort in two groups of patients receiving intensive drug therapy for HIV infection.
- Trial name
- NCT00001948
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV Seropositivity
Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST
Evaluation of antiretroviral treatment adherence using determination of Bictegravir, Emtricitabine and Tenofovir with new HIV patients in France
- Trial name
- FAST (NCT03858478)
- Testing
- Biktarvy arm
- Where
- 17 sites in France
- Volunteers
- 110 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
HIV Infections
A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.
To compare the safety, tolerance, early antiviral activity, and durability of antiviral response of the lamivudine (3TC)/zidovudine (ZDV)/1592U89 arm versus the 3TC/ZDV/indinavir (IDV) arm.
- Trial name
- NCT00002199
- Testing
- Indinavir sulfate, Lamivudine/Zidovudine, Abacavir sulfate
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Glaxo Wellcome
HIV Infections
The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
The purpose of this study is to evaluate the safety and tolerability of giving IL-2 plus anti-HIV (antiretroviral) therapy to HIV-positive patients with CD4 cell counts (cells of the immune system that fight infection) of at…
- Trial name
- NCT00000825
- Testing
- Aldesleukin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Analytic Treatment Interruption (ATI) to Assess HIV Cure
This study is designed to determine if individual patients with HIV infection have been cured of the infection. To do this, antiretroviral therapy is discontinued under close medical supervision and the patient monitored over…
- Trial name
- NCT02437526
- Testing
- Analytic treatment interruption
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.